Log in to save to my catalogue

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates e...

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates e...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8363276

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia

About this item

Full title

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia

Publisher

Ann Arbor: American Society for Clinical Investigation

Journal title

The Journal of clinical investigation, 2021-08, Vol.131 (16), p.1-16

Language

English

Formats

Publication information

Publisher

Ann Arbor: American Society for Clinical Investigation

More information

Scope and Contents

Contents

Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell deficiencies that hamper the expansion, persistence, and effector function of these cells. We used longitudinal immune profiling to identify phenotypic and pharmacodynamic changes in CD19-directe...

Alternative Titles

Full title

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8363276

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8363276

Other Identifiers

ISSN

1558-8238,0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI145459

How to access this item